All In Biotech

Drug Trial Radar · NCT07557498

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

362

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

Dec 14, 2026

Study completion Jun 17, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

  • MavacamtenDrug

    According to the product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant blood pressure (both systolic and diastolic)Time frame: Baseline
  2. Date of diagnosis of hypertrophic cardiomyopathyTime frame: Baseline
  3. Hypertrophic cardiomyopathy genetic testing resultsTime frame: Baseline
  4. Family history of hypertrophic cardiomyopathyTime frame: Baseline
  5. Family history of Sudden Cardiac Death (SCD)Time frame: Baseline
  6. Participant comorbidities (cardiovascular and non-cardiovascular )Time frame: Baseline
  7. Type of prior surgeries and proceduresTime frame: Baseline and up to week 24
  8. Participant New York Heart Association (NYHA) class categoryTime frame: Baseline, and at weeks 4, 8, 12, 24
  9. Change in participant New York Heart Association (NYHA) class from baselineTime frame: Baseline, and at weeks 4, 8, 12, 24
  10. Duration of mavacamten treatmentTime frame: Baseline, and at weeks 4, 8, 12, 24
  11. Number of mavacamten dose titrationsTime frame: Baseline, and at weeks 4, 8, 12, 24
  12. Type of mavacamten dose tritrationTime frame: Baseline, and at weeks 4, 8, 12, 24
  13. Clinical reason for mavacamten dose titrationTime frame: Baseline, and at weeks 4, 8, 12, 24
  14. Clinical reason for mavacamten treatment discontinuationTime frame: Baseline, and at weeks 4, 8, 12, 24
  15. Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,Time frame: Baseline, and at weeks 4, 8, 12, 24
  16. Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recoveryTime frame: Baseline, and at weeks 4, 8, 12, 24
  17. Clinical reason for temporary mavacamten treatment interuptionTime frame: Baseline, and at weeks 4, 8, 12, 24
  18. Time to temporary mavacamten treatment interruptionTime frame: Baseline, and at weeks 4, 8, 12, 24
  19. Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%Time frame: Baseline, and at weeks 4, 8, 12, 24
  20. Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recoveryTime frame: Baseline, and at weeks 4, 8, 12, 24
  21. Time to mavacamten treatment resumptionTime frame: Baseline, and at weeks 4, 8, 12, 24
  22. Type of hypertrophic cardiomyopathy (HCM) background therapy prescribedTime frame: Baseline, and at weeks 4, 8, 12, 24
  23. Type of changes to hypertrophic cardiomyopathy (HCM) background therapyTime frame: At baseline, weeks 4, 8, 12, 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Adelphi Real World

    Bollington, Macclesfield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.